3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
22
Phase 3
2
Phase 1
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Phase 1/2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Polycystic Ovary Syndrome
21
Insulin Resistance
5
Obesity
4
Neoplasms
3
Prostatic Neoplasms
2
Motor Activity
2
Menstruation Disturbances
2
Medulloblastoma
2
Infertility
2
Diabetes Mellitus
2
Breast Neoplasms
2
Weight Loss
1
Vitamin D Deficiency
1
Triple Negative Breast Neoplasms
1
Toxemia
1
Thyroid Neoplasms
1
Premature Birth
1
Pregnancy Complications
1
Prediabetic State
1
Pre-Eclampsia
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-DM Stage II High-risk Colorectal Cancer
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metabolic Syndrome
1
Liver Neoplasms
1
Infertility, Female
1
Hyperinsulinism
1
Hyperandrogenism
1
Interventions
Prednisone
53
Radiotherapy
52
Docetaxel
51
Leuprolide
48
Goserelin
47
bicalutamide
45
enzalutamide
28
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
27
Androgen Antagonists
27
Flutamide
24
Triptorelin Pamoate
22
apalutamide
18
Gonadotropin-Releasing Hormone
18
Abiraterone Acetate
17
Radiation
15
abiraterone
14
Zoledronic Acid
14
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
12
Prednisolone
11
luprolide acetate gel depot
10
darolutamide
9
Radiosurgery
9
cabazitaxel
8
Standard of Care
8
Specimen Handling
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Estramustine
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms
×
Metformin
×
Clear all
NCT03031821
2024-10-04
PRIME
Canadian Urologic Oncology Group
Phase 3
Terminated
168 enrolled
NCT01864096
2024-01-24
MAST
University Health Network, Toronto
Phase 3
Unknown
408 enrolled